Contraception for Specific Populations

Contraception After Pregnancy, endorsed by the Royal Colleges: GPs; Obstetricians and Gynaecologists; Nurses and Midwives, aims to guide healthcare professionals to inform and support the women in their care to make planned choices about future pregnancies and improve maternal and child outcomes through optimum spacing between children.

FSRH Clinical Guideline: Contraception After Pregnancy Executive Summary (January 2017)

This new document aims to summarise the available evidence on contraceptive choices for women who are overweight and women with obesity (i.e. with body mass index 25 kg/m2 or higher). This guideline evaluates the interrelationship between contraception and weight and considerations such as bariatric surgery and weight loss medication.

This guidance provides evidence-based recommendations and good practice points for health professionals providing contraceptive services to young people in the UK. This guidance is most relevant to young people under 18 years of age but may also apply to young people up to the age of 25 years.

The recent article in the Telegraph newspaper has highlighted the complex issues surrounding sexual activity in young women in the UK. Whilst it is true that the legal age of consent to sexual activity in the UK is 16 years, surveys suggest that almost one in three young people will have had sexual intercourse by this age.

This update of the 2010 Contraception for Women Aged Over 40 Years guideline has been developed by the FSRH and brings together evidence and expert opinion on contraception for women aged over 40 years. The guideline was developed with a team of experts in the relevant fields and has been extensively peer reviewed in accordance with methodology used for developing FSRH Clinical Guidelines. The guidance is intended for use by health professionals working in SRH, general practice and obstetric and gynaecology settings. This guideline was amended in September 2019.

This guidance provides evidence-based recommendations and good practice points for health professionals providing contraceptive services to women with cardiac disease in the UK.

This document was issued in late October 2016.

This document was published in October 2016.

This statement provides guidance on contraceptive options for women with prolactinoma

Updated Document - Please note, this document was updated in September 2016.

This statement aims to encourage the consistent and safe management of women requesting intrauterine contraception (IUC) and subdermal implants (SDI) who are taking anticoagulants or antiplatelet medications. It is primarily aimed at clinicians working in primary care and community sexual and reproductive health clinics.

This statement provides guidance on contraceptive options for women taking (or whose male partners are taking) known teratogenic drugs or drugs with potential teratogenic effects. Download the full document and save.

Sexually active women of reproductive age with eating disorders require effective contraception despite the fact that amenorrhoea and anovulation are common in this population. This statement provides clinicians with a resource for best helping women with eating disorders choose the most appropriate and acceptable contraception for them. Download and save the document here.

This statement provides guidance on contraceptive choices for transgender and non-binary people and their partners, who are engaging in vaginal sex where there is a risk of pregnancy. The statement also offers general sexual health advice for these groups.